10 Penny Stocks With Huge Upside Potential According To Analysts

2. OS Therapies Incorporated (NYSEAMERICAN:OSTX)

Average Upside Potential as of March 20: 820.25%

Number of Hedge Fund Holders: 1

Founded in 2018, OS Therapies Incorporated (NYSEAMERICAN:OSTX) is a biopharmaceutical company based in Rockville, Maryland, working on treatments for osteosarcoma and other solid tumors. The company’s pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma, and OST-tADC, a flexible antibody-drug conjugate platform. OSTX ranks second on our list of the penny stocks with the biggest upside.

On February 20, OS Therapies Incorporated (NYSEAMERICAN:OSTX) secured a USPTO patent for OST-HER2’s manufacturing, ensuring market exclusivity until 2040. Following a successful Phase 2b trial, it plans to seek FDA approval in 2025. OST-HER2 has received important regulatory designations, and the company aims to launch it for osteosarcoma, sell its Priority Review Voucher, and expand into breast cancer. The market potential is estimated at over $500 million for osteosarcoma and more than $1 billion for breast cancer. After raising $7.1 million in early 2025, OSTX has enough funding to operate through mid-2026.

OS Therapies Incorporated (NYSEAMERICAN:OSTX) had a significant third quarter, completing its IPO and finishing a major clinical trial for its cancer treatment, OST-HER2. The company said it will share trial results in December 2024 and work with the FDA to bring this potential treatment to patients as soon as possible. OS Therapies hopes to make money by selling a special FDA voucher and licensing its treatments. The company reported a $2.875 million loss in Q3 2024, mainly due to IPO costs, compared to a $2.006 million loss in Q3 2023.